Inflammatory process of the airways evidenced by episodic and reversible airflow obstruction and hyper-responsiveness with many cells and cellular elements contributing to the disease:
Neutrophils
Mast cells
Eosinophils
Macrophages
T lymphocytes
Epithelial cells
Cytokines
Triggers:
Pollen
Dust mites
Molds
Animal dander
Other environmental allergens
Viral upper respiratory infections
Occupational chemicals
Tobacco smoke
Environmental change
Cold air
Exercise induced
Emotional factors
Menstrual associated
Drugs:
Aspirin
NSAIDs
β-blockers
DIAGNOSIS SIGNS AND SYMPTOMS
Wheezing
Dyspnea
Chest tightness
Cough
Tachypnea
Tachycardia
Respiratory distress:
Posture sitting upright or leaning forward
Use of accessory muscles
Inability to speak in full sentences
Diaphoresis
Poor air movement
Impending failure:
Altered mental status
Worsening fatigue
Pulsus paradoxus >18 mm Hg
ESSENTIAL WORKUP
Primarily a clinical diagnosis
Measure and follow severity with peak expiratory flow rate (PEFR)
Assess for underlying disease
DIAGNOSIS TESTS & NTERPRETATION Lab
Arterial blood gas:
Not helpful during the initial evaluation
The decision to intubate should be based on clinical criteria.
Mild–moderate asthma: Respiratory alkalosis
Severe airflow obstruction and fatigue: Respiratory acidosis and PaCO 2 >42
Pulse oximetry:
<90% is indicative of severe respiratory distress.
Patients with impending respiratory compromise may still maintain saturation above 90% until sudden collapse.
WBC:
Leukocytosis is nonspecific
Pneumonia
Chronic steroid use
Stress of an asthma exacerbation
Demargination occurs after administration of epinephrine and steroids.
Diagnostic Procedures/Surgery
PEFR:
Estimates the degree of airflow obstruction:
Normal peak flow (adult) is 400–600.
100–300 indicates moderate airway obstruction.
<100 is indicative of severe airway obstruction.
Use serially as an objective measure of the response to therapy
Forced expiratory volume (FEV):
More reliable measure of lung function than PEFR
Difficult to use as a screening tool
Often unavailable in the ED
Severe airway obstruction: FEV 1 <30–50%
CXR:
Indications:
Fever
Suspicion of pneumonia
Suspicion of pneumothorax or pneumomediastinum
Foreign body aspiration
1st episode of asthma
Comorbid illness: For example: Diabetes, renal failure, CHF, AIDS, cancer
Not responding to treatment
Typical findings:
Hyperinflation
Scattered atelectasis
ECG:
Indicated in patients at risk for cardiac disease:
Dysrhythmias
Myocardial ischemia
Transient changes in severe asthma:
Right axis deviation
Right bundle branch block
Abnormal P-waves
Nonspecific ST–T-wave changes
DIFFERENTIAL DIAGNOSIS
Allergic reaction
Angioedema
Bronchiolitis
Bronchitis
Carcinoid tumors
Chemical pneumonitis
Chronic cor pulmonale
Chronic obstructive pulmonary disease
CHF
Croup
Foreign body aspiration
Immersion injury
Myocardial ischemia
Pneumonia
Pulmonary embolus
Smoke inhalation
Upper airway obstruction
Venous air embolus
TREATMENT PRE HOSPITAL
Recognize the “quiet chest” as respiratory distress.
Supplemental oxygen
Continuous nebulized β-agonist
Administration of IM/SC epinephrine
INITIAL STABILIZATION/THERAPY
Immediate initiation of inhaled β-agonist treatment
Intubate for fatigue and respiratory distress.
Steroids
ED TREATMENT/PROCEDURES
Oxygen:
Maintain an oxygen saturation >90%
β-adrenergic agonist:
Selective β 2 -agonists (albuterol)
Mild–moderate asthmatic: Administer every 20 min
Severe asthmatic: Continuous nebulized treatment
SC β-agonist (terbutaline and epinephrine):
Severe exacerbations
Limited inhalation of aerosolized medicine
More side effects because of systemic absorption
Terbutaline—longer acting β-2 agonist with bronchodilating effects equivalent to epinephrine in acute asthma.
Relative contraindication: Age >40 yr and coronary disease
Corticosteroids:
Reduce airway wall inflammation
Administered early
Onset of action may take 4–6 hr
Administer IV or PO
IV Solu-Medrol in the treatment of severe asthma exacerbation
Mild–moderate exacerbations may be treated with oral prednisone burst or Depo-Medrol IM
Inhaled corticosteroids are currently not recommended as initial therapy.
Anticholinergic agents:
If minimal response to initial β-agonist treatment
Severe airflow obstruction
Inhaled anticholinergic agents should be used in conjunction with β-agonists.
Magnesium sulfate:
No benefit in mild–moderate asthma
May have a benefit in severe asthma
Aminophylline:
Rare utility in acute management
Leukotriene inhibitors:
Not currently recommended for acute exacerbation
Heliox:
Mixture of helium and oxygen (80:20, 70:30, 60:40)
Less dense than air
Decrease airway resistance.
Decrease in respiratory exhaustion
Not currently recommended for routine use
Consider in severe asthma
Noninvasive positive pressure ventilation:
CPAP and BiPAP
May improve oxygenation and decrease respiratory fatigue
Can only be used in an alert patient
Should not replace intubation
Not currently recommended for routine use
Consider in severe asthma
Ketamine:
Bronchodilator and an anesthetic agent
Useful as an induction agent during intubation
Contraindications:
HTN
Coronary disease
Preeclampsia
Increased intracranial pressure
Halothane:
Inhalation anesthetics are potent bronchodilators.
Refractory asthma in intubated patients
Intubation of the asthmatic patient:
Rapid sequence intubation
Lidocaine to attenuate airway reflexes
Etomidate or ketamine as an induction agent
Succinylcholine should be administered to achieve paralysis.
A large endotracheal tube >7 mm should be used to facilitate ventilation.
May need to mechanically exhale for the patient
Permissive hypercapnia
MEDICATION
β-agonists
Albuterol: 2.5 mg in 2.5 mL NS q20min inhaled (peds: 0.1–0.15 mg/kg/dose q20min [min. dose 1.25 mg])
Epinephrine: Adult: 0.3 mg (1:1,000) SC q0.5h–q4h × 3 doses (peds: 0.01 mg/kg up to 0.3 mg SC)
Terbutaline: 0.25 mg SC q0.5h × 2 doses (peds: 0.01 mg/kg up to 0.3 mg SC)
Corticosteroids:
Methylprednisolone: 60–125 mg IV (peds: 1–2 mg/kg/dose IV or PO q6h × 24 h)
Prednisone: 40–60 mg PO (peds: 1–2 mg/kg/d in single or divided doses)
Depo-Medrol 160 mg IM
Anticholinergics
Ipratropium bromide: 0.5 mg in 3 mL NS q1h × 3 doses
Magnesium: 2 g IV over 20 min (peds: 25–75 mg/kg)
Aminophylline: 0.6 mg/kg/h IV infusion
Rapid sequence intubation:
Etomidate: 0.3 mg/kg IV, or ketamine: 1–1.5 mg/kg IV